The Tetracyclo Ring System Consists Of Four Six-membered Cyclos Patents (Class 549/277)
-
Patent number: 9546122Abstract: Monomers, polymers and copolymers are provided that incorporate at least one naturally occurring phenolic compound, such as a plant phenol.Type: GrantFiled: March 11, 2014Date of Patent: January 17, 2017Assignee: NDSU Research FoundationInventors: Bret Ja Chisholm, Samim Alam, Satyabrata Samanta
-
Patent number: 9388155Abstract: The disclosure provides methods and compositions for treating and preventing cancer using 6-substituted coumarin derivatives. The coumarin derivatives of the disclosure have substituents at the 6-position with five carbon atoms or greater. The coumarin derivatives may be further substituted and may be 3,4-dihydrocoumarins. In preferred embodiments, the coumarin derivatives of the disclosure are used to treat pancreatic cancer.Type: GrantFiled: March 14, 2014Date of Patent: July 12, 2016Assignee: Wellesley CollegeInventor: Dora Carrico-Moniz
-
Publication number: 20140243404Abstract: This disclosure is related to halonium compounds useful for cyclization of polyenes, alkenoic acids, and alkenyl alkyl ethers, and halogenation of aromatic compounds. The synthesis of such halonium compounds, compounds made using such halonium compounds, and synthesis of natural compounds, including decalins, using the halonium compounds is also disclosed.Type: ApplicationFiled: September 13, 2011Publication date: August 28, 2014Applicant: The Trustees of Columbia University in the City of New YorkInventors: Scott Alan Snyder, Daniel S. Treitler, Alexandria P. Brucks, Andreas Gollner, Maria I. Chiriac, Nathan E. Wright, Jason J. Pflueger, Steven P. Breazzano
-
Patent number: 8801939Abstract: A method for increasing ozone concentration in a liquid can include: providing a gas having ozone; introducing the ozone-containing gas into a liquid, wherein the liquid and ozone combination has a temperature between about 0.8 and about 1.5 times the critical temperature of ozone; and increasing isothermally, the pressure of the ozone-containing gas above the liquid to about 0.3 to about 5 times the critical pressure of ozone so as to increase the ozone concentration in the liquid. The temperature is expressed in absolute units (Kelvin or Rankin). The method can be used for removing ozone from a gas or for purifying ozone. The liquid having a high ozone concentration can be used for ozonolysis of a substrate.Type: GrantFiled: April 19, 2013Date of Patent: August 12, 2014Assignees: University of Kansas, Archer Daniels Midland CompanyInventors: Bala Subramaniam, Daryle Busch, Andrew M. Danby, Thomas P Binder
-
Publication number: 20130251647Abstract: The invention relates to new types of modulators of the cold menthol receptor TRPM8, to methods of modulating the TRPM8 receptor using these modulators; and in particular the use of the modulators for inducing a sensation of coldness; and also the articles and compositions produced using these modulators.Type: ApplicationFiled: September 20, 2012Publication date: September 26, 2013Applicant: BASF SEInventors: Thomas Subkowski, Claus Bollschweiler, Jens Wittenberg, Wolfgang Siegel, Ralf Pelzer
-
Patent number: 8425784Abstract: A method for increasing ozone concentration in a liquid can include: providing a gas having ozone; introducing the ozone-containing gas into a liquid, wherein the liquid and ozone combination has a temperature between about 0.8 and about 1.5 times the critical temperature of ozone; and increasing isothermally, the pressure of the ozone-containing gas above the liquid to about 0.3 to about 5 times the critical pressure of ozone so as to increase the ozone concentration in the liquid. The temperature is expressed in absolute units (Kelvin or Rankin). The method can be used for removing ozone from a gas or for purifying ozone. The liquid having a high ozone concentration can be used for ozonolysis of a substrate.Type: GrantFiled: November 4, 2008Date of Patent: April 23, 2013Assignees: University of Kansas, Archer Daniels Midland CompanyInventors: Bala Subramaniam, Daryle Busch, Andrew M. Danby, Thomas P. Binder
-
Publication number: 20110263693Abstract: Based on the discovery that celastrol and gedunin are Hsp90 inhibitors, the present invention provides novel inhibitors of Hsp90. and pharmaceutically acceptable salts, derivatives, and compositions thereof. The invention provides two classes of compounds. One class includes celastrol and its derivatives. The other class includes gedunin and its derivatives. The present invention further provides methods for treating disorders wherein Hs?90 inhibition is desired (e.g., proliferative diseases, cancer, inflammatory diseases, fungal infections, etc.) comprising administering a therapeutically effective amount of an inventive compound to a subject in need thereof. Celastrol, gedunin, and derivatives thereof are particularly useful in the treatment of prostate cancer, breast cancer, ovarian cancer, lung cancer, and leukemia.Type: ApplicationFiled: March 30, 2007Publication date: October 27, 2011Applicants: DANA-FARBER CANCER INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Haley Vinson-Hieronymus, Todd R. Golub, Justin Lamb, Kimberly Stegmaier
-
TETRACYCLIC DIPYRANO-COUMARIN COMPOUNDS WITH ANTI-HIV AND ANTI-MYCOBACTERIUM TUBERCULOSIS ACTIVITIES
Publication number: 20100324067Abstract: The present invention relates to tetracyclodipyrano-coumarin compounds of general formula (I), wherein the substituents are defined herein. These compounds exihibit dual biological activities of anti human immunodeficiency virus type 1 (HIV-1) infection and anti-Mycobacterium Tuberculosis (TB) infection.Type: ApplicationFiled: November 5, 2007Publication date: December 23, 2010Inventors: Gang Liu, Hai Xue, Tao Ma, Ziwei Chen, Lin Wang -
Publication number: 20090118498Abstract: A method for increasing ozone concentration in a liquid can include: providing a gas having ozone; introducing the ozone-containing gas into a liquid, wherein the liquid and ozone combination has a temperature between about 0.8 and about 1.5 times the critical temperature of ozone; and increasing isothermally, the pressure of the ozone-containing gas above the liquid to about 0.3 to about 5 times the critical pressure of ozone so as to increase the ozone concentration in the liquid. The temperature is expressed in absolute units (Kelvin or Rankin). The method can be used for removing ozone from a gas or for purifying ozone. The liquid having a high ozone concentration can be used for ozonolysis of a substrate.Type: ApplicationFiled: November 4, 2008Publication date: May 7, 2009Inventors: Bala Subramaniam, Daryle Busch, Andrew M. Danby, Thomas P. Binder
-
Publication number: 20080221202Abstract: The present invention is directed to novel steroid derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by at least one progesterone or glucocorticoid receptor.Type: ApplicationFiled: March 6, 2008Publication date: September 11, 2008Inventors: Nareshkumar F. Jain, Zhihua Sui, Ningyi Chen
-
Patent number: 6949561Abstract: A sulphamate compound suitable for use as an inhibitor of oestrone sulphatese (E.C.3.1.6.2) is described. The compound is a polycyclic compound comprising at least two ring components, wherein the polycyclic compound comprises at least one sulphamate group attached to at least one of the ring components, and wherein at least one of the ring components of the polycyclic structure is a heterocyclic ring.Type: GrantFiled: May 17, 2000Date of Patent: September 27, 2005Assignee: Sterix LimitedInventors: Michael John Reed, Barry Victor Lloyd Potter
-
Patent number: 6777562Abstract: The method of the invention comprises a process for synthesizing a trans-calanolide A ketone intermediate used in the synthesis of racemic trans-calanolide A. The invention further comprises a method for removing a racemic calanolide B diastereomer from a mixture of calanolide A and calanolide B diastereomers formed in the last step of the synthesis of calanolide A by crystallization.Type: GrantFiled: February 19, 2003Date of Patent: August 17, 2004Assignee: Dow Global Technologies Inc.Inventor: Edward D. Daugs
-
Patent number: 6673830Abstract: The present invention provides novel antiviral compounds, refered to as calanolides, related compounds, and their derivatives, which may be isolated from plants, or derived from compounds from plants, of the genus Calophyllum in accordance with the present inventive method. The compounds and their derivatives may be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2.Type: GrantFiled: June 22, 2001Date of Patent: January 6, 2004Assignees: The United States of America as represented by the Secretary of Health and Human Services, The Board of Trustees of the University of IllinoisInventors: Michael R. Boyd, John H. Cardellina, II, Kirk R. Gustafson, James B. McMahon, Richard W. Fuller, Gordon M. Cragg, Yoel Kashman, Doel Soejarto
-
Patent number: 6670383Abstract: The present invention relates to compounds and compositions useful in treating or preventing conditions and diseases related to Mycobacterium infection, and methods of use directed thereto.Type: GrantFiled: March 15, 2002Date of Patent: December 30, 2003Assignee: Advanced Life Sciences, Inc.Inventors: Ze-Qi Xu, Krzysztof Pupek, Livia Enache, Michael T. Flavin
-
Patent number: 6369241Abstract: The present invention relates to methods for preparing 2,2-dimethyl-5-acyloxy-10-propyl-2H,8H-benzo[1,2-b:3,4-b′]dipyran-8-one (5) and 2,2-dimethyl-5-hydroxy-10-propyl-2H,8H-benzo[1,2-b:3,4-b′]dipyran-8-one (6) and their use as intermediates for the synthesis of antiviral calanolide compounds. For example, Fries rearrangement on compound 5 or Friedel-Crafts reaction on 6, yields intermediate 2,2-dimethyl-5-hydroxy-6-propionyl-10-propyl-2H,8H-benzo[1,2-b:3,4-b′]dipyran-8-one (4), which, in turn, can be converted to (+)-calanolide A and (−)-calanolide B. The coupling of compound 6 with the appropriate chiral molecule under Mitsunobu or nucleophilic displacement leads to the asymmetric synthesis of antiviral calanolide compounds.Type: GrantFiled: April 25, 2000Date of Patent: April 9, 2002Assignee: Sarawak Medichem Pharmaceuticals, Inc.Inventors: Ze-Qi Xu, Hongwei Yuan, Jennifer Crabb, Raghu Samy, Ailing Li, Hua Cao
-
Publication number: 20020013478Abstract: Calanolide analogues that demonstrate potent antiviral activity against many viruses are provided. Also provided is a method of using calanolide analogues for treating or preventing viral infections. The calanolide analogues provided are obtained via syntheses employing chromene 4 and chromanone 7 as key intermediates.Type: ApplicationFiled: March 21, 2001Publication date: January 31, 2002Applicant: Sarawak Medichem Pharmaceuticals,Inc.Inventors: Ze-Qi Xu, Michael T. Flavin, David Zembower
-
Patent number: 6277879Abstract: Calanolide analogues that demonstrate potent antiviral activity against many viruses are provided. Also provided is a method of using calanolide analogues for treating or preventing viral infections. The calanolide analogues provided are obtained via syntheses employing chromene 4 and chromanone 7 as key intermediates.Type: GrantFiled: October 15, 1998Date of Patent: August 21, 2001Assignee: Sarawak Medichem Pharmaceuticals, Inc.Inventors: Ze-Qi Xu, Michael T. Flavin, David Zembower
-
Patent number: 6160131Abstract: An efficient and scalable method is reported for the isolation of costatolide (2), an HIV-1-specific nonnucleoside reverse transcriptase inhibitor (NNRTI), from the latex of Calophyllum plants such as C. teysmannii var. inophylloide. An overall yield of 10.6% of costatolide, with a purity of 96%, was obtained by repetitive recrystallization of the latex from a single organic solvent after the oily material was removed by treatment with hexane. A second major component of the latex, soulattrolide (3), another HIV-1 NNRTI, was also isolated. Both compounds were characterized by spectroscopic and chromatographic analyses and their in vitro anti-HIV activities were also confirmed. The results suggest that sufficient supplies of costatolide can be obtained in a relatively low-cost manner from natural sources.Type: GrantFiled: December 17, 1998Date of Patent: December 12, 2000Assignee: Sarawak Medichem Pharmaceuticals, Inc.Inventors: Yuh-Meei Lin, Herbert M. Anderson, Tuah R. Jenta, Michael J. Williams, Michael T. Flavin, Ze-Qi Xu
-
Patent number: 6087347Abstract: Estratriene derivatives of the following formula have a powerful inhibitory effect on estrone sulfatase and are hence useful for the prophylaxis or treatment of diseases caused by estrogens, such as breast cancer, uterine cancer, ovarian cancer, endometriosis, adenomyosis uteri and mastopathy. ##STR1## wherein one of A and B represents C.dbd.O or CH.sub.2 and the other represents O or NH; and R represents --SO.sub.2 NR.sup.1 R.sup.2 or --PO(OM).sub.2 in which R.sup.1 and R.sup.2 each independently represent a hydrogen atom or a lower alkyl group and M represents a hydrogen atom or an alkali metal; provided that, when one of A and B represents NH, the other represents C.dbd.O.Type: GrantFiled: March 12, 1999Date of Patent: July 11, 2000Assignee: Teikoku Hormone Mfg. Co., Ltd.Inventors: Naoyuki Koizumi, Shigehiro Takegawa, Shigeki Iwashita, Tomoko Kawachi, Mamoru Mieda, Tomohito Fujii
-
Patent number: 6043271Abstract: A method of preparing (.+-.)-calanolide A, 1, a potent HIV reverse transcriptase inhibitor, from chromene 4 is provided. Useful intermediates for preparing (.+-.)-calanolide A and its derivatives are also provided. According to the disclosed method, chromene 4 intermediate was reacted with acetaldehyde diethyl acetal or paraldehyde in the presence of an acid catalyst with heating, or a two-step reaction including an aldol reaction with acetaldehyde and cyclization either under acidic conditions or neutral Mitsunobu conditions, to produce chromanone 7. Reduction of chromanone 7 with sodium borohydride, in the presence of cerium trichloride, produced (.+-.)-calanolide A. A method for resolving (.+-.)-calanolide A into its optically active forms by a chiral HPLC system or by enzymatic acylation and hydrolysis is also disclosed. Finally, a method for treating or preventing a viral infections using (.+-.)-calanolide or (-)-calanolide is provided.Type: GrantFiled: August 2, 1995Date of Patent: March 28, 2000Assignee: Sarawak MediChem Pharmaceuticals, Inc.Inventors: Michael T. Flavin, Ze-Qi Xu, John D. Rizzo, Alla Kucherenko, Albert Khilevich, Abram Kivovich Sheinkman, Vilayphone Vilaychack, Lin Lin, Wei Chen, William A. Boulanger
-
Patent number: 6022497Abstract: Described are novel photochromic six-membered heterocyclic-fused naphthopyran compounds, examples of which are naphthopyran compounds having a substituted or unsubstituted six-membered heterocyclic group fused to one side of the naphtho portion of the naphthopyran and having certain substituents at the position ortho to the oxygen atom of the naphthopyran ring. These compounds may be represented by the following graphic formula: ##STR1## Also described are polymeric organic host materials that contain or that are coated with such compounds or combinations thereof with complementary photochromic compounds, e.g., certain other naphthopyrans, benzopyrans, and spiro(indoline) type compounds.Type: GrantFiled: March 19, 1999Date of Patent: February 8, 2000Assignee: PPG Industries Ohio, Inc.Inventor: Anil Kumar
-
Patent number: 5892060Abstract: A method of preparing (+)-calanolide A, 1, a potent HIV reverse transcriptase inhibitor, from chromene 4 is provided. According to the disclosed method, chromene 4 intermediate was subjected to a chlorotitanium-mediated aldol reaction with acetaldehyde to selectively produce (.+-.)-8a. Separation and enzyme-mediated resolution of (.+-.)-8a produced (+)-8a. Cyclization of (+)-8a under neutral Mitsunobu conditions followed by Luche reduction of (+)-7 produced (+)-calanolide A in high yield and enantiomeric purity. The method of the invention has been extended to produce potent antiviral calanolide A analogues.Type: GrantFiled: March 1, 1996Date of Patent: April 6, 1999Assignee: Sarawak MediChem Pharmaceuticals, Inc.Inventors: Michael T. Flavin, Ze-Qi Xu, Albert Khilevich, David Zembower, John D. Rizzo, Shuyuan Liao, Aye Mar, Lin Lin, Vilayphone Vilaychak, Darko Brankovic, Sergey Dzekhster, Jinjun Liu
-
Patent number: 5872264Abstract: A method of preparing (+)-calanolide A, 1, a potent HIV reverse transcriptase inhibitor, from chromene 4 is provided. According to the disclosed method, chromene 4 intermediate was subjected to a chlorotitanium-mediated aldol reaction with acetaldehyde to selectively produce (.+-.)-8a. Separation and enzyme-mediated resolution of (.+-.)-8a produced (+)-8a. Cyclization of (+)-8a under neutral Mitsunobu conditions followed by Luche reduction of (.+-.)-7 produced (+)-calanolide A in high yield and enantiomeric purity. The method of the invention has been extended to produce potent antiviral calanolide A analogues.Type: GrantFiled: September 5, 1997Date of Patent: February 16, 1999Assignee: Sarawak MediChem Pharmaceuticals, Inc.Inventors: Michael T. Flavin, Ze-Qi Xu, Albert Khilevich, David Zembower, John D. Rizzo, Shuyuan Liao, Aye Mar, Lin Lin, Vilayphone Vilaychack, Darko Brankovic, Sergey Dzekhster, Jinjun Liu
-
Patent number: 5847164Abstract: A method of preparing (.+-.)-calanolide A, 1, a potent HIV reverse transcriptase inhibitor, from chromene 4 is provided. Useful intermediates for preparing (.+-.)-calanolide A and its derivatives are also provided. According to the disclosed method, chromene 4 intermediate was reacted with acetaldehyde diethyl acetal or paraldehyde in the presence of an acid catalyst with heating, or a two-step reaction including an aldol reaction with acetaldehyde and cyclization either under acidic conditions or neutral Mitsunobu conditions, to produce chromanone 7. Reduction of chromanone 7 with sodium borohydride, in the presence of cerium trichloride, produced (.+-.)-calanolide A. A method for resolving (.+-.)-calanolide A into its optically active forms by a chiral HPLC system or by enzymatic acylation and hydrolysis is also disclosed. Finally, a method for treating or preventing viral infections using (.+-.)-calanolide A or (-)-calanolide A is provided.Type: GrantFiled: September 9, 1997Date of Patent: December 8, 1998Assignee: Sarawak MediChem Pharmaceuticals, Inc.Inventors: Michael T. Flavin, Ze-Qi Xu, John D. Rizzo, Albert Khilevich, Abram Kivovich Sheinkman
-
Patent number: 5723631Abstract: The present invention relates to a process for the preparation of a compound of the following structure: ##STR1## wherein, substituents are as defined in the specification.Type: GrantFiled: June 22, 1995Date of Patent: March 3, 1998Assignee: SmithKline Beecham CorporationInventors: Ashok Dharmaji Patil, Robert Philip Hertzberg, Geoffrey B. Dreyer, Alan James Freyer, John W. Westley, Balan Chenera, Michael Leo West
-
Patent number: 5608085Abstract: A method of synthesis of the four optically active stereoisomers of calanolide A and B which produces the compounds in high yields and in a high degree of purity.Type: GrantFiled: February 27, 1995Date of Patent: March 4, 1997Assignee: The University of Tennessee Research CorporationInventors: David C. Baker, Prashant P. Deshtande, Shijia Yan, Frank Tagliaferri, Samuel F. Victory
-
Patent number: 5591770Abstract: The present invention provides novel antiviral compounds, refered to as calanolides, related compounds, and their derivatives, which may be isolated from plants, or derived from compounds from plants, of the genus Calophyllum in accordance with the present inventive method. The compounds and their derivatives may be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2.Type: GrantFiled: May 21, 1993Date of Patent: January 7, 1997Assignees: The United States of America as represented by the Department of Health and Human Services, The Board of Trustees of the University of IllinoisInventors: Michael R. Boyd, John H. Cardellina, II, Kirk R. Gustafson, James B. McMahon, Richard W. Fuller, Gordon M. Cragg, Yoel Kashman, Doel Soejarto
-
Patent number: 5565147Abstract: Described are novel reversible photochromic diaryl-3H-naphtho[2,1-b]pyran compounds having a substituted or unsubstituted, five or six member heterocyclic ring fused to the g, i, or l side of the naphthopyran. The heterocyclic ring contains an oxygen or nitrogen atom and is attached to the number 5, 6, 7, 8, 9, or 10 carbon atom of the naphtho portion of the naphthopyran. Also described are organic host materials containing such compounds. Articles such as ophthalmic lenses or other plastic transparencies that incorporate the novel naphthopyran compounds or combinations thereof with complementary photochromic compounds, e.g., spiro(indoline)oxazine-type compounds, are also described.Type: GrantFiled: June 2, 1995Date of Patent: October 15, 1996Assignee: Transitions Optical, Inc.Inventors: David B. Knowles, Barry Van Gemert
-
Patent number: 5340552Abstract: A macroreticulate polymer is provided for removing water vapor and oxidants from a gas having the formula: ##STR1## wherein Ar is a heteroaromatic moiety, M is bonded to the heteroaromatic moiety and is selected from the group consisting of lithium, sodium, potassium, alkyl magnesium, alkyl zinc, and dialkylaluminum, R is an organic moiety and R.sub.1 is a polymerized moiety forming the molecular backbone of said polymer.Type: GrantFiled: September 10, 1992Date of Patent: August 23, 1994Assignee: Millipore CorporationInventor: James T. Snow
-
Patent number: 5180840Abstract: A process for synthesizing oxygen-containing polyoxatetracycle compounds and in particular analogs of the antimalarial agent known as qinghaosu or artemisinin is disclosed. The process employs as a reactant an olefinically unsaturated bicyclic bridging ketone having nonenolizable bridgehead moieties for both of its alpha positions. This ketone is converted to a vinylsilane that is subjected to ozonolytic cleavage of its olefinic bond to yield a member of a family of unique carboxyl/carbonyl-substituted vinylsilanes which may in turn optionally be subjected to a wide range of reactions prior to a final ozonolysis/acidification step which closes the oxygen-containing ring structure. The various intermediates are claimed as aspects of this invention as are novel tetracycles and their use as antimalarials.Type: GrantFiled: February 19, 1991Date of Patent: January 19, 1993Assignee: SRI InternationalInventors: Mitchell A. Avery, Wesley K. M. Chong
-
Patent number: 5091501Abstract: This invention provides a process for producing 2H-1-benzopyran-2-ones (coumarins) from optionally-substituted o-halocinnamic acids or esters under polyester-forming conditions. When the coumarins contain appropriately reactive functional groups, and desired monomers are present, a colored or UV-absorbing coumarin/polyester copolymer is provided in one step.Type: GrantFiled: October 4, 1990Date of Patent: February 25, 1992Assignee: Eastman Kodak CompanyInventors: Max A. Weaver, Samuel D. Hilbert, Wayne P. Pruett, Clarence A. Coates, Jr.
-
Patent number: 5041558Abstract: An accelerator of the activity of hydrolase consisting of a coordination compound or a metal complex containing, as a ligand, an organic cyclic compound with carbonyl groups adjacent to each other in the structure shown in the following general formula I that are substantially in the same plane as each other; ##STR1## (wherein A is the cyclic compound moiety.Type: GrantFiled: April 10, 1987Date of Patent: August 20, 1991Assignee: Sekisui Kagaku Kogyo Kabushiki KaishaInventor: Hideo Anraku
-
Patent number: 5019590Abstract: A process for synthesizing oxygen-containing polyoxatetracycle compounds and in particular analogs of the antimalarial agent known as qinghaosu or artemisinin is disclosed. The process employs as a reactant an olefinically unsaturated bicyclic bridging ketone having nonenolizable bridgehead moieties for both of its alpha positions. This ketone is converted to a vinylsilane that is subjected to ozonolytic cleavage of its olefinic bond to yield a member of a family of unique carboxyl/carbonyl-substituted vinylsilanes which may in turn optionally be subjected to a wide range of reactions prior to a final ozonolysis/acidification step which closes the oxygen-containing ring structure. The various intermediates are claimed as aspects of this invention as are novel tetracycles and their use as antimalarials.Type: GrantFiled: September 27, 1989Date of Patent: May 28, 1991Assignee: SRI InternationalInventors: Mitchell A. Avery, Wesley K. M. Chong
-
Patent number: 4963683Abstract: A process for synthesizing polyoxa tetracyclics which involves the ozonolysis of a single-ring-structure vinyl silane with resulting direct formation of the desired multiple ring matrial. The polyoxa tetracyclic compounds have the formula ##STR1## The vinyl silanes have the structure ##STR2## The vinyl silanes are new chemical compounds as are corresponding primary ozonide and dioxetane intermediates. In a preferred embodiment, this invention provides a total synthesis of the antimalarial artemisinin.Type: GrantFiled: February 15, 1989Date of Patent: October 16, 1990Assignee: SRI InternationalInventors: Mitchell A. Avery, Clive Jennings-White
-
Patent number: 4599409Abstract: The present invention relates to new bisamidine derivatives of polycyclic compounds such as 5,10-dioxo-4,5,9,10-tetrahydro-4,9-dioxapyrene-6(5H)-phenanthridone and 5,10-dioxo-4,5,9,10-tetrahydro-4,9-dioxapyrenephenanthridine and to a process for their preparation. The polycyclic bisamidines according to the invention are distinguished by valuable chemotherapeutic properties, such as, for example, an action against amoebas and trichomonads.Type: GrantFiled: February 15, 1984Date of Patent: July 8, 1986Assignee: Hoechst AktiengesellschaftInventors: Balbir S. Bajwa, deceased, Dipak K. Chatterjee, Bimal N. Ganguli, Jurgen Reden, Noel J. de Souza